Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$129.50 USD

129.50
949,567

+1.81 (1.42%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $129.00 -0.50 (-0.39%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (58 out of 244)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Zacks Equity Research

Here's Why You Should Add HealthEquity (HQY) to Your Portfolio

by Zacks Equity Research

HealthEquity's (HQY) strength in HSA raises optimism about the stock.

Indrajit Bandyopadhyay headshot

Medical Device Stocks' Earnings Due on Feb 13: ECL, DVA & QDEL

by Indrajit Bandyopadhyay

Medical Device companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how ECL, DVA and QDEL fare this time.

Zacks Equity Research

DaVita (DVA) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the fourth quarter.

Zacks Equity Research

Here's Why You Should Invest in Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) on strength across the target market and upbeat guidance.

Zacks Equity Research

IDEXX's (IDXX) Global Growth Continues, Currency Woes Persist

by Zacks Equity Research

A key element of IDEXX's (IDXX) customer engagement strategy is the expansion of its commercial footprint in a disciplined approach.

Zacks Equity Research

Insulet's (PODD) Omnipod 5 Gets CE Mark for Added Compatibility

by Zacks Equity Research

Insulet's (PODD) tubeless automated insulin delivery system's CE mark approval with multiple CGM sensor brands is likely to serve a wider patient pool.

Zacks Equity Research

Is Ardelyx (ARDX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Ardelyx (ARDX) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

Zacks Equity Research

Hologic (HOLX) Introduces Genius Digital Diagnostics System

by Zacks Equity Research

Hologic's (HOLX) Genius Digital Diagnostics System will assist laboratories and healthcare providers with the information needed to make more timely and successful treatment decisions for patients.

Zacks Equity Research

Three Reasons to Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches raises optimism about the stock.

Zacks Equity Research

Edwards Lifesciences (EW) Wins FDA Nod for the EVOQUE System

by Zacks Equity Research

Edwards Lifesciences' (EW) EVOQUE valve replacement system becomes the first transcatheter therapy to earn FDA approval for a tricuspid valve.

Zacks Equity Research

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Strength of the base business bodes well for Quest Diagnostics (DGX).

Zacks Equity Research

Modular Medical (MODD) Pairing Technology Issued New U.S. Patent

by Zacks Equity Research

Modular Medical's (MODD) latest U.S. patent is likely to protect the company's technology addressing pairing and allow clinicians to easily upload and review patients' data.

Zacks Equity Research

Boston Scientific's (BSX) FARAPULSE PFA System Gets FDA Nod

by Zacks Equity Research

Boston Scientific (BSX) secures FDA approval for the FARAPULSE PFA system.

Zacks Equity Research

Trinity Biotech (TRIB) to Grow in Wearable Biosensor With Buyout

by Zacks Equity Research

Trinity Biotech's (TRIB) focus on CGM as an initial step, utilizing a device with regulatory approval, provides a de-risked entry point in the wearable biosensor technology space.

Zacks Equity Research

Insulet (PODD) Gains From Product Innovation, Global Expansion

by Zacks Equity Research

Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.

Zacks Equity Research

The Zacks Analyst Blog Highlights Arista Networks, Chipotle Mexican Grill, Netflix, DaVita and Royal Caribbean Cruises

by Zacks Equity Research

Arista Networks, Chipotle Mexican Grill, Netflix, DaVita and Royal Caribbean Cruises are part of the Zacks top Analyst Blog.

Zacks Equity Research

Are Investors Undervaluing DaVita (DVA) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

BD's (BDX) Tie-Up to Offer AI-Based Digital System for Pap Test

by Zacks Equity Research

BD's (BDX) latest partnership is likely to aid cytotechnologists and pathologists to efficiently identify evidence of cervical cancer and pre-cancerous lesions.

Zacks Equity Research

Thermo Fisher (TMO) End Market Growth Strong Despite Macro Woes

by Zacks Equity Research

Thermo Fisher's (TMO) electron microscopy, chromatography and mass spectrometry businesses are delivering strong growth in the academic and government end market.

Tirthankar Chakraborty headshot

Strong January is a Good Omen for Wall Street: 5 Growth Picks

by Tirthankar Chakraborty

As the S&P 500 is poised to finish January in the green and continue its winning streak, investing in some growth stocks such as Arista Networks (ANET), Netflix (NFLX) and DaVita (DVA) seems judicious.

Zacks Equity Research

QIAGEN (QGEN) Forges Alliance to Advance Microbiome Sciences

by Zacks Equity Research

QIAGEN (QGEN) announces a first-in-kind collaboration with Penn State University to help shape research, education and outreach in microbiomes.

Zacks Equity Research

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business.

Zacks Equity Research

Philips (PHG) Q4 Earnings Beat Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Philips' (PHG) fourth-quarter results benefit from strong momentum across the Diagnosis & Treatment and Personal Health businesses. However, softness in the Connected Care business is a concern.

Zacks Equity Research

Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Ethan Feller headshot

Momentum Monday: FOMC, Big-Tech Earnings, and QRA

by Ethan Feller

Want to start the week ahead of the pack? Check out Momentum Mondays